-
Mashup Score: 38
Not available.
Source: haematologica.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2ATTR Amyloidosis: 1 in 4 Patients Experience Neurological and Cardiac Symptoms - Patient Worthy - 9 day(s) ago
Don’t miss this story about the latest ATTR amyloidosis research.
Source: patientworthy.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18
Background: Amyloidosis is a complex multi-systemic disease. Lack of knowledge about amyloidosis and subsequent mis- or under-diagnosis are major obstacles to treatment, which result in life-threatening organ damage, morbidity, and mortality. Hence, the purpose of this study is to explore the …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 13The More Things Change, the More They Stay the Same - 28 day(s) ago
Two drugs’ rejections a decade apart have highlighted challenges in drug development in amyloidosis. Tackling these challenges will …
Source: arci.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Treatment Overview: Light Chain (AL) Amyloidosis - 2 month(s) ago
Understand the latest information about current types of AL amyloidosis treatments and different options to consider. This booklet is …
Source: arci.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11
Friday, March 1, 2024 Medical Professional ConferenceTarget Audience: Cardiologists, hematologists, neurologists, nephrologists, pulmonologists, hepatologists, nurse practitioners, nurses, social workers, transplant coordinators, and trainees in these subspecialitiesIn-person and virtual attendance options availableClick here to register!
Source: learn.houstonmethodist.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2
Limited data exists on the prognostic impact of valvular heart disease in cardiac amyloidosis (CA). We therefore sought to define the prevalence of va…
Source: www.sciencedirect.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 50Practical Points for Echocardiography in Cardiac Amyloidosis - 3 month(s) ago
This document was created by an American Society of Echocardiography Amyloidosis Taskforce as a practical accompaniment to the recently published multisociety Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.1,2 In this document we will outline the common echocardiographic imaging findings of cardiac amyloidosis (CA), highlighting red flags that should raise suspicion for the diagnosis. We will also provide tips for image acquisition and interpretation. Based on the comprehensive multisociety document on imaging of CA,1,2 this document will also provide recommendations for standard reporting of an echocardiogram in a patient with CA.
Source: www.onlinejase.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 49Practical Points for Echocardiography in Cardiac Amyloidosis - 3 month(s) ago
This document was created by an American Society of Echocardiography Amyloidosis Taskforce as a practical accompaniment to the recently published multisociety Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.1,2 In this document we will outline the common echocardiographic imaging findings of cardiac amyloidosis (CA), highlighting red flags that should raise suspicion for the diagnosis. We will also provide tips for image acquisition and interpretation. Based on the comprehensive multisociety document on imaging of CA,1,2 this document will also provide recommendations for standard reporting of an echocardiogram in a patient with CA.
Source: www.onlinejase.comCategories: General Medicine News, Cardiology News and JournTweet
Great to see prospective data on Dara-Vd in Stage IIIb AL #Amyloidosis! Hematologic and organ response comparable to ANDROMEDA and 2-year OS~65% (historically ~20%)! Proves that we can now successfully treat even stage IIIb! https://t.co/vvY0zqh4iR https://t.co/BR45DlmV9o https://t.co/GriqMN91Gh